Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%
10:04am, Tuesday, 08'th Aug 2023
Jared Holz, Mizuho healthcare sector strategist, joins 'Squawk Box' to discuss the impact of Novo Nordisk's weight-loss drug Wegovy cuts risk of heart attack or stroke by 20%, the obesity drug market
Novo Nordisk weight loss drug impresses in heart trial
09:38am, Tuesday, 08'th Aug 2023
Novo Nordisk (NYSE:NVO) shares soared as the Danish pharma reported its new treatment Wegovy reduced heart problems well as weight in on ongoing trial. Obesity treatment semaglutide (marketed as Wegov
Wegovy's success in reducing cardio risk is ‘an important win,' and a ‘best-case scenario,' say Wolfe analysts
08:02am, Tuesday, 08'th Aug 2023
The success of Novo Nordisk's NVO, +3.04% NOVO.B, +13.49% Wegovy in reducing cardiovascular events in obese adults is an important win for the obesity category with positive implications for that comp
Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%
07:37am, Tuesday, 08'th Aug 2023
The results of the trial were seen as a major boost for the firm's hopes of moving beyond Wegovy's image as a "vanity drug."
Novo Nordisk says Wegovy reduced risk of adverse cardiovascular events by 20% in adults with obesity in trial
06:19am, Tuesday, 08'th Aug 2023
Novo Nordisk's U.S.-listed stock NVO, +3.04% NOVO.B, +10.32% rose 10% premarket Tuesday, after the company said its obesity treatment semaglutide, marketed as Wegovy, met its main goal in a trial eval
People are 'scratching and clawing' for negative narrative around obesity drugs: Mizuho's Jared Holz
06:42pm, Monday, 07'th Aug 2023
Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to talk Eli Lilly earnings, obesity drug demand and more.
Novo Nordisk A/S: A Biotech Giant with High Outperformance Potential
03:02pm, Monday, 07'th Aug 2023
Novo Nordisk A/S ( NVO , Financial), a leading player in the biotechnology industry, is currently trading at $161.48 with a market capitalization of $361.61 billion. The company's stock price has seen
3 ‘Strong Buy' Stocks You Should Be Loading Up On Now
05:44am, Monday, 07'th Aug 2023
The stock market in 2023 is like night and day compared to last year. After rallying sharply from last September's low points, the Dow Jones Industrial Average, S&P 500 and Nasdaq 100 are each up over
Novo Nordisk Stock Isn't a Bargain. Here's Why You Should Buy It Anyway.
10:15am, Friday, 04'th Aug 2023
Novo Nordisk's valuation is fairly high thanks to its newest weight-loss medicines. Given that it has other medications on the way, its valuation could hold up.
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
05:50am, Wednesday, 02'nd Aug 2023
A recent survey found that doctors are most excited about semaglutide in treating NASH. Treating the liver disease could be a massive market over the next few years.
Buy These 3 Top-Ranked Stocks for Dividend Growth
05:55pm, Tuesday, 01'st Aug 2023
Companies that pay dividends are often well-established, as they generally are no longer experiencing supercharged growth and opt to share profits with shareholders.
Is a Surprise Coming for Novo Nordisk (NVO) This Earnings Season?
01:26pm, Tuesday, 01'st Aug 2023
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Novo Nordisk Stock Thrashed the Market on Monday
05:27pm, Monday, 31'st Jul 2023
The Ozempic developer detailed its recent share buybacks. It launched a repurchase program at the end of January.
Novo Nordisk weight-loss drug Wegovy launched in Germany, first big EU market
10:39am, Saturday, 29'th Jul 2023
Novo Nordisk has launched blockbuster weight-loss drug Wegovy in Germany, its first big European market, hoping Germans will pay hundreds of euros out of pocket for a drug that public health insurance
3 Biotech Stocks to Buy Before Drug Trials End
12:56pm, Friday, 28'th Jul 2023
Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to receive FDA approval.
